Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy

Ryuichi Mizuno, Akira Miyajima, Taizo Hibi, Aya Masuda, Toshiaki Shinojima, Eiji Kikuchi, Masahiro Jinzaki, Mototsugu Oya

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The aim of this study was to evaluate the clinical significance of visceral fat accumulation as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapies. A total of 114 patients were retrospectively reviewed. All patients received systemic therapy for mRCC at Keio University hospital in Japan. The intra-abdominal visceral fat area was determined by computed tomography at the umbilical level. The visceral fat accumulation was defined as ≥100 cm2. The mean visceral fat area was 107.4 ± 62.8 cm2. In the whole cohort, the median follow-up was 29 months. According to the Memorial Sloan Kettering Cancer Center (MSKCC) classification, 27.2% patients were favorable risk, 53.5% were intermediate risk, and 19.3% were poor risk. Visceral fat accumulation correlated with improved progression-free (P = 0.0070) and overall survival (P = 0.0001). On multivariate analysis, visceral fat accumulation (P = 0.0290) and MSKCC classification (P = 0.0085) were independent indices to predict progression-free survival in first-line treatment. In addition, visceral fat accumulation (P = 0.0007) and MSKCC classification (P = 0.0005) independently predicted overall survival. Prognostic grouping using visceral fat accumulation was identified as an independent prognostic marker in patients with mRCC. The addition of visceral fat accumulation improved the prognostic value of MSKCC classification alone in predicting overall survival in patients treated with systemic therapy for mRCC.

Original languageEnglish
Article number47
JournalMedical Oncology
Volume34
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Intra-Abdominal Fat
Renal Cell Carcinoma
Therapeutics
Survival
Neoplasms
Umbilicus
Disease-Free Survival
Japan
Multivariate Analysis
Tomography

Keywords

  • Metastasis
  • Molecular targeted therapy
  • Outcome
  • Renal cell carcinoma
  • Visceral fat

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy. / Mizuno, Ryuichi; Miyajima, Akira; Hibi, Taizo; Masuda, Aya; Shinojima, Toshiaki; Kikuchi, Eiji; Jinzaki, Masahiro; Oya, Mototsugu.

In: Medical Oncology, Vol. 34, No. 4, 47, 01.04.2017.

Research output: Contribution to journalArticle

@article{fc8f573d62fb44c9bf5e276b89d0b8b8,
title = "Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy",
abstract = "The aim of this study was to evaluate the clinical significance of visceral fat accumulation as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapies. A total of 114 patients were retrospectively reviewed. All patients received systemic therapy for mRCC at Keio University hospital in Japan. The intra-abdominal visceral fat area was determined by computed tomography at the umbilical level. The visceral fat accumulation was defined as ≥100 cm2. The mean visceral fat area was 107.4 ± 62.8 cm2. In the whole cohort, the median follow-up was 29 months. According to the Memorial Sloan Kettering Cancer Center (MSKCC) classification, 27.2{\%} patients were favorable risk, 53.5{\%} were intermediate risk, and 19.3{\%} were poor risk. Visceral fat accumulation correlated with improved progression-free (P = 0.0070) and overall survival (P = 0.0001). On multivariate analysis, visceral fat accumulation (P = 0.0290) and MSKCC classification (P = 0.0085) were independent indices to predict progression-free survival in first-line treatment. In addition, visceral fat accumulation (P = 0.0007) and MSKCC classification (P = 0.0005) independently predicted overall survival. Prognostic grouping using visceral fat accumulation was identified as an independent prognostic marker in patients with mRCC. The addition of visceral fat accumulation improved the prognostic value of MSKCC classification alone in predicting overall survival in patients treated with systemic therapy for mRCC.",
keywords = "Metastasis, Molecular targeted therapy, Outcome, Renal cell carcinoma, Visceral fat",
author = "Ryuichi Mizuno and Akira Miyajima and Taizo Hibi and Aya Masuda and Toshiaki Shinojima and Eiji Kikuchi and Masahiro Jinzaki and Mototsugu Oya",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s12032-017-0908-3",
language = "English",
volume = "34",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy

AU - Mizuno, Ryuichi

AU - Miyajima, Akira

AU - Hibi, Taizo

AU - Masuda, Aya

AU - Shinojima, Toshiaki

AU - Kikuchi, Eiji

AU - Jinzaki, Masahiro

AU - Oya, Mototsugu

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The aim of this study was to evaluate the clinical significance of visceral fat accumulation as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapies. A total of 114 patients were retrospectively reviewed. All patients received systemic therapy for mRCC at Keio University hospital in Japan. The intra-abdominal visceral fat area was determined by computed tomography at the umbilical level. The visceral fat accumulation was defined as ≥100 cm2. The mean visceral fat area was 107.4 ± 62.8 cm2. In the whole cohort, the median follow-up was 29 months. According to the Memorial Sloan Kettering Cancer Center (MSKCC) classification, 27.2% patients were favorable risk, 53.5% were intermediate risk, and 19.3% were poor risk. Visceral fat accumulation correlated with improved progression-free (P = 0.0070) and overall survival (P = 0.0001). On multivariate analysis, visceral fat accumulation (P = 0.0290) and MSKCC classification (P = 0.0085) were independent indices to predict progression-free survival in first-line treatment. In addition, visceral fat accumulation (P = 0.0007) and MSKCC classification (P = 0.0005) independently predicted overall survival. Prognostic grouping using visceral fat accumulation was identified as an independent prognostic marker in patients with mRCC. The addition of visceral fat accumulation improved the prognostic value of MSKCC classification alone in predicting overall survival in patients treated with systemic therapy for mRCC.

AB - The aim of this study was to evaluate the clinical significance of visceral fat accumulation as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapies. A total of 114 patients were retrospectively reviewed. All patients received systemic therapy for mRCC at Keio University hospital in Japan. The intra-abdominal visceral fat area was determined by computed tomography at the umbilical level. The visceral fat accumulation was defined as ≥100 cm2. The mean visceral fat area was 107.4 ± 62.8 cm2. In the whole cohort, the median follow-up was 29 months. According to the Memorial Sloan Kettering Cancer Center (MSKCC) classification, 27.2% patients were favorable risk, 53.5% were intermediate risk, and 19.3% were poor risk. Visceral fat accumulation correlated with improved progression-free (P = 0.0070) and overall survival (P = 0.0001). On multivariate analysis, visceral fat accumulation (P = 0.0290) and MSKCC classification (P = 0.0085) were independent indices to predict progression-free survival in first-line treatment. In addition, visceral fat accumulation (P = 0.0007) and MSKCC classification (P = 0.0005) independently predicted overall survival. Prognostic grouping using visceral fat accumulation was identified as an independent prognostic marker in patients with mRCC. The addition of visceral fat accumulation improved the prognostic value of MSKCC classification alone in predicting overall survival in patients treated with systemic therapy for mRCC.

KW - Metastasis

KW - Molecular targeted therapy

KW - Outcome

KW - Renal cell carcinoma

KW - Visceral fat

UR - http://www.scopus.com/inward/record.url?scp=85013226767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013226767&partnerID=8YFLogxK

U2 - 10.1007/s12032-017-0908-3

DO - 10.1007/s12032-017-0908-3

M3 - Article

VL - 34

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 4

M1 - 47

ER -